PAH
Phenylalanine-4-hydroxylase
Also known as: PH, PH4H_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P00439
- Gene
- PAH
- Ensembl
- ENSG00000171759
- Chromosome
- 12
- Canonical length
- 452 aa
- Protein class
- Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Endoplasmic reticulum,Vesicles
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a member of the biopterin-dependent aromatic amino acid hydroxylase protein family. The encoded phenylalanine hydroxylase enzyme hydroxylates phenylalanine to tyrosine and is the rate-limiting step in phenylalanine catabolism. Deficiency of this enzyme activity results in the autosomal recessive disorder phenylketonuria. [provided by RefSeq, Aug 2017]
Canonical amino-acid sequenceUniProt
452 residues, UniProt reviewed canonical sequence.
>P00439|PAH
1 MSTAVLENPG LGRKLSDFGQ ETSYIEDNCN QNGAISLIFS LKEEVGALAK VLRLFEENDV
61 NLTHIESRPS RLKKDEYEFF THLDKRSLPA LTNIIKILRH DIGATVHELS RDKKKDTVPW
121 FPRTIQELDR FANQILSYGA ELDADHPGFK DPVYRARRKQ FADIAYNYRH GQPIPRVEYM
181 EEEKKTWGTV FKTLKSLYKT HACYEYNHIF PLLEKYCGFH EDNIPQLEDV SQFLQTCTGF
241 RLRPVAGLLS SRDFLGGLAF RVFHCTQYIR HGSKPMYTPE PDICHELLGH VPLFSDRSFA
301 QFSQEIGLAS LGAPDEYIEK LATIYWFTVE FGLCKQGDSI KAYGAGLLSS FGELQYCLSE
361 KPKLLPLELE KTAIQNYTVT EFQPLYYVAE SFNDAKEKVR NFAATIPRPF SVRYDPYTQR
421 IEVLDNTQQL KILADSINSE IGILCSALQK IKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PAH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 1,317 nTPM
Expression across tissuesHPA
Tissue
- liver: 1,317 nTPM
- kidney: 464 nTPM
- gallbladder: 75 nTPM
- pancreas: 8.2 nTPM
- adrenal gland: 6 nTPM
- cerebral cortex: 5.3 nTPM
Single-cell type
- hepatocytes: 1,063 nCPM
- proximal tubule cells: 435 nCPM
- cholangiocytes: 264 nCPM
- early spermatids: 185 nCPM
- late primary spermatocytes: 143 nCPM
- corticotrophs: 102 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 4.9 nTPM
- cerebral cortex: 4.5 nTPM
- white matter: 4.5 nTPM
- spinal cord: 4.2 nTPM
- thalamus: 4.2 nTPM
- hypothalamus: 3.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PAH.
Disease | AllUniProt
Conditions PAH is implicated in, by any mechanism.
- Phenylalanine hydroxylase deficiency (PAH deficiency) MIM:261600
Disease | GeneticClinVar
897 pathogenic / likely-pathogenic of 1,698 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Phenylketonuria
- PAH-related disorder
- Inborn genetic diseases
- Hyperphenylalaninemia
- See cases
ReferencesPubMed · IEDB
Publications for PAH from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.
2023 · J Pers Med · RCR 1.9 · 13 citations - Pteridin-dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type I.
2000 · J Clin Endocrinol Metab · RCR 0.7 · 27 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.5
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.65
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- catecholamine biosynthetic process
- L-phenylalanine catabolic process
- amino acid biosynthetic process
- tyrosine biosynthetic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aromatic amino acid hydroxylase
- ACT domain
- Aromatic amino acid hydroxylase, iron/copper binding site
- Tyrosine 3-monooxygenase-like
- Aromatic amino acid hydroxylase, C-terminal
- Aromatic amino acid monoxygenase, C-terminal domain superfamily
- Aromatic amino acid hydroxylase superfamily
- ACT-like domain
- Biopterin-dependent aromatic amino acid hydroxylase
- Phenylalanine-4-hydroxylase, tetrameric form
- Eukaryotic phenylalanine-4-hydroxylase, catalytic domain
- ACT domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PAH as an antibody target. Whether an autoantibody or antibody against PAH could matter depends on whether native PAH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PAH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PAH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...